| Literature DB >> 33805078 |
Thitianan Kulsirirat1, Sittisak Honsawek2, Mariko Takeda-Morishita3, Nuttanan Sinchaipanid4, Wanvisa Udomsinprasert5, Jiraporn Leanpolchareanchai1, Korbtham Sathirakul1.
Abstract
Andrographolide is a labdane diterpenoid herb, which is isolated from the leaves of Andrographis paniculata, and widely used for its potential medical properties. However, there are no reports on the effects of andrographolide on the human suprapatellar fat pad of osteoarthritis patients. In the present study, our goal was to evaluate the innovative effects of andrographolide on viability and Tri-lineage differentiation of human mesenchymal stem cells from suprapatellar fat pad tissues. The results revealed that andrographolide had no cytotoxic effects when the concentration was less than 12.5 µM. Interestingly, andrographolide had significantly enhanced, dose dependent, osteogenesis and chondrogenesis as evidenced by a significantly intensified stain for Alizarin Red S, Toluidine Blue and Alcian Blue. Moreover, andrographolide can upregulate the expression of genes related to osteogenic and chondrogenic differentiation, including Runx2, OPN, Sox9, and Aggrecan in mesenchymal stem cells from human suprapatellar fat pad tissues. In contrast, andrographolide suppressed adipogenic differentiation as evidenced by significantly diminished Oil Red O staining and expression levels for adipogenic-specific genes for PPAR-γ2 and LPL. These findings confirm that andrographolide can specifically enhance osteogenesis and chondrogenesis of mesenchymal stem cells from human suprapatellar fat pad tissues. It has potential as a therapeutic agent derived from natural sources for regenerative medicine.Entities:
Keywords: andrographolide; mesenchymal stem cells; osteoarthritis; regenerative medicine; suprapatellar fat pad
Year: 2021 PMID: 33805078 PMCID: PMC8037192 DOI: 10.3390/molecules26071831
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Figure 1Cells morphology from SPFP tissue at 21st day of 1st passage under light microscope (4×).
Figure 2Flow cytometry analysis of the expression of cell surface markers protein in SPFP-MSCs from three OA patients. Cell cultures were positive for the MSC specific markers (A) CD29 = 92.30 ± 3.20%, (B) CD73 = 90.91 ± 2.73%, and (C) CD105 = 83.52 ± 3.23%. and negative for the hematopoietic stem cell markers (D) CD 34 = 1.04 ± 2.88% and (E) CD45 = 0.92 ± 1.08%.
Figure 3The effect of AG on cell viability of cells from SPFP-MSCs. The bar means SD. Data is shown as mean ± SD (n = 10). * Significant difference, p-value ≤ 0.05.
Figure 4The effects of different doses of AG (1, 5 and 10 μM) with specific induction medium (IM) of each differentiation type on tri-lineage differentiation potentials of cells from SPFP-MSCs on day 21 compared with specific induction medium without AG as control. The scale bar (▬▬) in (A,B,D–F) represents 500 µm and 200 µm, respectively. (A) Osteogenic differentiation; Alizarin red S staining reflected that the calcium droplets. (B) Adipogenic differentiation; Oil Red O staining reflected that lipid droplets. (C) Chondrogenic differentiation; After a cell pellet was treated with chondrogenic medium and chondrogenic medium with AG. (D) Pellet cultures of SPFP-MSCs were sectioned and stained with Hematoxylin & Eosin reflected that morphology. (E) Pellet cultures of SPFP-MSCs were sectioned and stained with toluidine blue reflected that glycosaminoglycans. (F) Pellet cultures of SPFP-MSCs were sectioned and stained with alcian blue reflected that proteoglycans.
Figure 5The effects of different doses of AG (1,5 and 10 µM) on tri-lineage differentiation potentials of cells from SPFP tissues on day 21. (A) Osteogenic differentiation: (Runx2, OPN), (B) Adipogenic differentiation: (PPAR-γ2, LPL), (C) Chondrogenic differentiation: (Sox9, Aggrecan). Gene expression of tri-lineage potentials was assessed using real-time PCR. The bar means SD. Data is shown as mean ± SD (n = 10). Statistical significance was calculated using a one-way ANOVA test and significance is represented on graphs as * p-value < 0.05.
Baseline characteristics of patients in the current study.
| Patient No. | Age | Sex | Diagnosis |
|---|---|---|---|
| 1 | 81 | Female | Osteoarthritis |
| 2 | 75 | Male | Osteoarthritis |
| 3 | 61 | Female | Osteoarthritis |
| 4 | 78 | Female | Osteoarthritis |
| 5 | 76 | Female | Osteoarthritis |
| 6 | 86 | Female | Osteoarthritis |
| 7 | 77 | Female | Osteoarthritis |
| 8 | 83 | Female | Osteoarthritis |
| 9 | 75 | Female | Osteoarthritis |
| 10 | 81 | Female | Osteoarthritis |
Primer oligonucleotide sequences used for real-time PCR.
| Gene | Forward Primer 5-3 | Reverse Primer 5-3 |
|---|---|---|
| Runx2 | 5′TATGGCACTTCTTCAGGATCC′3 | 5′GCGTCAACACCATCATTCTGG′3 |
| OPN | 5′TGAAACGAGTCAGCTGGATG′3 | 5′TGAAATTCATGGCTGTGGAA′3 |
| PPAR-γ2 | 5′GCTGTTATGGGTGAAACTCTG′3 | 5′ATAAGGTGGAGATGCAGGCTC′3 |
| LPL | 5′GAGATTTCTCTGTATGGCACC′3 | 5′CTGCAAATGAGACACTTTCTC′3 |
| Sox9 | 5′ATCTGAAGAAGGAGAGCGAG′3 | 5′TCAGAAGTCTCCAGAGCTTG′3 |
| Aggrecan | 5′TGAGGAGGGCTGGAACAAGTACC′3 | 5′GGAGGTGGTAATTGCAGGGAACA′3 |
| GAPDH | 5′GTGAAGGTCGGAGTCAACGG′3 | 5′TCAATGAAGGGGTCATTGATGG′3 |